Bezlotoxumab
Generic Name: bezlotoxumab
Brand Names:
Zinplava
11 DESCRIPTION Bezlotoxumab is a human monoclonal antibody that binds to C. difficile toxin B and neutralizes its effects. Bezlotoxumab is an IgG 1 immunoglobulin with an approximate molecular weight of 148.2 kDa. ZINPLAVA (bezlotoxumab) Injection is a sterile, preservative-free, clear to moderately opalescent, colorless to pale yellow solution that requires dilution for intravenous infusion. The product is provided in a 50 mL vial that contains 1000 mg of bezlotoxumab in 40 mL of solution.
Overview
11 DESCRIPTION Bezlotoxumab is a human monoclonal antibody that binds to C. difficile toxin B and neutralizes its effects. Bezlotoxumab is an IgG 1 immunoglobulin with an approximate molecular weight of 148.2 kDa. ZINPLAVA (bezlotoxumab) Injection is a sterile, preservative-free, clear to moderately opalescent, colorless to pale yellow solution that requires dilution for intravenous infusion. The product is provided in a 50 mL vial that contains 1000 mg of bezlotoxumab in 40 mL of solution.
Uses
1 INDICATIONS AND USAGE ZINPLAVA™ is indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence. ZINPLAVA is a human monoclonal antibody that binds to Clostridioides difficile toxin B, indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence. ( 1 ) Limitation of Use: ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA is not an antibacterial drug. ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI.
Dosage
2 DOSAGE AND ADMINISTRATION Administer ZINPLAVA during antibacterial drug treatment for CDI. ( 2.1 ) The recommended dose is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes. ( 2.2 ) Dilute prior to intravenous infusion. Administer via a low-protein binding 0.2 micron to 5 micron in-line or add-on filter. See Full Prescribing Information for dilution and administration instructions. ( 2.3 ) 2.1 Important Administration Instructions Administer ZINPLAVA during antibacterial drug treatment for CDI. 2.2 Dosing Recommendations in Adults and Pediatric Patients 1 year of age and older The recommended dose of ZINPLAVA is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes.
Side Effects
6 ADVERSE REACTIONS Adult Patients : The most common adverse reactions (reported in ≥4% of adult patients) included nausea, pyrexia, and headache. ( 6.1 ) Pediatric Patients : The most common adverse reactions (reported in >10% of pediatric patients) were pyrexia and headache ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Interactions
7 DRUG INTERACTIONS Since ZINPLAVA is eliminated by catabolism, no metabolic drug-drug interactions are expected [see Clinical Pharmacology (12.3) ] .
Warnings
5 WARNINGS AND PRECAUTIONS Heart Failure : Was reported more commonly in ZINPLAVA-treated patients with a history of congestive heart failure (CHF) in Trial 1 and Trial 2. In patients with a history of CHF, ZINPLAVA should be reserved for use when the benefit outweighs the risk. ( 5.1 ) 5.1 Heart Failure Heart failure was reported more commonly in Trial 1 and Trial 2 in ZINPLAVA-treated patients compared to placebo-treated patients. These adverse reactions occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, 12.7% (15/118) of ZINPLAVA-treated patients and 4.8% (5/104) of placebo-treated patients had the serious adverse reaction of heart failure during the 12-week study period [see Adverse Reactions (6.1) ] . 4 CONTRAINDICATIONS None. None ( 4 )
Pregnancy
8.1 Pregnancy Risk Summary Adequate and well controlled studies with ZINPLAVA have not been conducted in pregnant women. No animal reproductive and developmental studies have been conducted with bezlotoxumab. The background risk of major birth defects and miscarriage for the indicated population is unknown; however, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
Storage
Store in a refrigerator, 2ºC to 8ºC (36ºF to 46ºF) in original carton to protect from light. Do Not Freeze. Do Not Shake.
Frequently Asked Questions
What is Bezlotoxumab used for?▼
1 INDICATIONS AND USAGE ZINPLAVA™ is indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence. ZINPLAVA is a human monoclonal antibody that binds to Clostridioides difficile toxin B, indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence. ( 1 ) Limitation of Use: ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA is not an antibacterial drug. ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI.
What are the side effects of Bezlotoxumab?▼
6 ADVERSE REACTIONS Adult Patients : The most common adverse reactions (reported in ≥4% of adult patients) included nausea, pyrexia, and headache. ( 6.1 ) Pediatric Patients : The most common adverse reactions (reported in >10% of pediatric patients) were pyrexia and headache ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Can I take Bezlotoxumab during pregnancy?▼
8.1 Pregnancy Risk Summary Adequate and well controlled studies with ZINPLAVA have not been conducted in pregnant women. No animal reproductive and developmental studies have been conducted with bezlotoxumab. The background risk of major birth defects and miscarriage for the indicated population is unknown; however, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
What are the important warnings for Bezlotoxumab?▼
5 WARNINGS AND PRECAUTIONS Heart Failure : Was reported more commonly in ZINPLAVA-treated patients with a history of congestive heart failure (CHF) in Trial 1 and Trial 2. In patients with a history of CHF, ZINPLAVA should be reserved for use when the benefit outweighs the risk. ( 5.1 ) 5.1 Heart Failure Heart failure was reported more commonly in Trial 1 and Trial 2 in ZINPLAVA-treated patients compared to placebo-treated patients. These adverse reactions occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, 12.7% (15/118) of ZINPLAVA-treated patients and 4.8% (5/104) of placebo-treated patients had the serious adverse reaction of heart failure during the 12-week study period [see Adverse Reactions (6.1) ] . 4 CONTRAINDICATIONS None. None ( 4 )
Related Medications
Alfalfa, Avena Sativa, Fucus Vesiculosus, Hordeum Vulgare, Nasturtium Aquaticum, Raphanus Sativus, Triticum Aestivum, Iodium, Ubidecarenonum, Glandula Suprarenalis Suis, Hepar Suis, Manganese Gluconate, Oryza Sativa, Thyroidinum (suis), Calcarea Carbonica, Natrum Muriaticum, Pulsatilla (pratensis), Rhus Tox, Cortisone Aceticum
alfalfa, avena sativa, fucus vesiculosus, hordeum vulgare, nasturtium aquaticum, raphanus sativus, triticum aestivum, iodium, ubidecarenonum, glandula suprarenalis suis, hepar suis, manganese gluconate, oryza sativa, thyroidinum (suis), calcarea carbonica, natrum muriaticum, pulsatilla (pratensis), rhus tox, cortisone aceticum
Non-Standardized Food Allergenic Extract [EPC]
INDICATIONS: For temporary relief of sinus congestion, dry cough in the evening and rhinitis.
Carbo Vegetabilis 12x,chamomilla 12x,foeniculum Vulgare 12x,lycopodium 30x,nux Moschata 12x,raphanus Sativus 12x,zingiber Officinale 12x,kali Muriaticum 6x,magnesia Phosphorica 12x,natrum Phosphoricum 6x
carbo vegetabilis 12x,chamomilla 12x,foeniculum vulgare 12x,lycopodium 30x,nux moschata 12x,raphanus sativus 12x,zingiber officinale 12x,kali muriaticum 6x,magnesia phosphorica 12x,natrum phosphoricum 6x
Non-Standardized Plant Allergenic Extract [EPC]
PURPOSE Temprorily Relieves: Colic Gas Pain Stomach & Gas Discomfort Irritability from Gas Stomach Acid Buildup Purpose
Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin, Rutinic Acid, Iodium, Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Spongia Tosta, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Lapis Albus
foeniculum vulgare, ammonium bromatum, fucus vesiculosus, lecithin, rutinic acid, iodium, capsicum annuum, galium aparine, hypothalamus suis, kali bichromicum, lac defloratum, phytolacca decandra, spongia tosta, thyroidinum (bovine), pituitarum posterium (bovine), antimonium crudum, argentum metallicum, calcarea carbonica, adrenalinum, phosphorus, lapis albus
Non-Standardized Plant Allergenic Extract [EPC]
PURPOSE: Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides thyroid support.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.